Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Seikagaku Aims at Sales of ¥30.5 Bil. in FY2011
November 22, 2010
- LTT Bio-Pharma Adds CSC Differentiation Inducer to Its R&D Pipeline
November 22, 2010
- Shionogi: Sales Up 8.1%, Net Profits Down 40.8%
November 15, 2010
- Crohn's Disease, Ankylosing Spondylitis Approved for Humira: Abbott, Eisai
November 15, 2010
- MTPC, Korosho Discussing Resumptionof of Marketing for Medway Inj.
November 15, 2010
- Ono: Sales Down 5.1% Due to Price Cuts, Competition with Generics
November 15, 2010
- Chuikyo Appreciates Efforts Made to Develop, Apply for Unapproved Drugs/Indications
November 15, 2010
- Shionogi Confident about Its Marketing Strategy in Japan
November 15, 2010
- Kissei: Long-Listed Products Struggle due to NHI Price Cuts
November 15, 2010
- Lucentis Recommended for Approval in EU for DME: Novartis
November 15, 2010
- Ono to Focus on Niche Cancer Markets
November 15, 2010
- Santen: Tapros Props Up Business
November 15, 2010
- Santen Developing New Combination Drug for Glaucoma
November 15, 2010
- Kaken: Artz Drives Sales, Profits
November 15, 2010
- Leuplin's Successor Enters PIII in the US: Takeda, Millennium
November 15, 2010
- Mochida: NHI Price Cuts Hit Business
November 15, 2010
- COP10 Adopts Nagoya Protocol
November 15, 2010
- Operating Profit Rate Up for 5 of Top Six Drug Wholesalers
November 15, 2010
- LATUDA Meets Efficacy Endpoints in 3rd PIII Trial
November 15, 2010
- Lurasidone Approval “Exceptionally Quick”: DSP President Tada
November 15, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…